Search the Newsreel

Lipocine Inc. (NASDAQ: LPCN) awards director 2,000 stock options

Lipocine Inc. (NASDAQ: LPCN) director Michael Grissinger was awarded 2,000 stock options on August 3, 2026, with an exercise price of $2.11 per share and an expiration date of August 3, 2036. The options have a vesting schedule, with one-third vesting on August 3, …

Lipocine Inc. (LPCN) director Grissinger files initial ownership statement

Lipocine Inc. director Michael Grissinger has filed an initial statement of beneficial ownership (Form 3). This filing indicates that Grissinger is a director but not an officer or a ten percent owner of the company, and it reports no current equity holdings or insider …

Lipocine Inc (LPCN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Lipocine Inc (LPCN) has an earnings forecast score of 7.00, ranking 306th in the Biotechnology & Medical Research industry. Analysts have set an average price target of $6.88, with a "Buy" rating based on the opinions of 2 analysts. The company's expected revenue for …

Lipocine Q2 2026 earnings: Missing license revenue drives top-line decline

Lipocine (NASDAQ: LPCN) reported a significant decline in Q2 2026 revenue to $190,099, primarily due to the absence of license revenue from the prior year, though TLANDO royalties increased. The company's net loss widened to $2.6 million, and attention is now focused on an …

Lipocine Inc (LPCN) Earnings Date & Reports & Earnings News

Lipocine Inc (NASDAQ: LPCN) Share Price, LPCN Stock News, LPCN Share Price & Updates

This article provides a comprehensive overview of Lipocine Inc. (NASDAQ: LPCN), including its current stock price, fundamental financial data, and peer comparison. It details the company's income statement, balance sheet, and cash flow for several years, highlighting its clinical-stage biopharmaceutical focus on CNS disorders …

Lipocine reports Q2 net loss $2.6M, cash and investments $23.3M as of June 30, 2026

Lipocine (LPCN) reported a Q2 2026 net loss of $2.6 million, or ($0.32) per diluted share, with $23.3 million in cash and investments as of June 30, 2026. The company generated $190,099 in total revenue from TLANDO royalty income. Key business highlights include progress …

Lipocine Inc. Q2 2026: Revenue $190099 EPS $(0.32) — 10-Q Summary

Lipocine Inc. reported its Q2 2026 financial results, with revenue of $190,099 and a net loss of $(2,622,595), resulting in a diluted EPS of $(0.32). Revenue significantly declined year-over-year due to a shift in revenue mix, despite progress in pipeline development and capital raising …

Lipocine Inc. (LPCN) Stock Price, News, Quote & History

This Yahoo Finance page provides comprehensive financial information for Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company. It includes real-time stock price data, historical performance, key financial metrics, an overview of the company's drug pipeline and research focus, and recent analyst insights. The company specializes …

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2026

Lipocine Inc. announced its financial results for the second quarter ended June 30, 2026, reporting a net loss of $2.6 million and detailing progress on its drug candidates. The company provided updates on LPCN 1154 for Postpartum Depression, LPCN 2201 for Major Depressive Disorder, …

Lipocine (NASDAQ: LPCN) widens H1 loss but extends cash runway to 2027

Lipocine Inc. reported a Q2 2026 revenue of $190,099 and a net loss of $2.6 million, with a H1 2026 loss of $6.3 million. Despite increased operating expenses due to higher R&D, the company has extended its cash runway to August 2027 after raising …

Lipocine: Q2 Earnings Snapshot

Lipocine earnings beat by $0.12, revenue topped estimates

Lipocine's Postpartum Depression Trial Did Not Meet Primary Endpoint

Lipocine appoints Michael Grissinger to board of directors

Lipocine Inc. has announced the appointment of Michael J. Grissinger to its Board of Directors. Grissinger brings extensive experience from Johnson & Johnson, where he held senior management roles in pharmaceutical licensing, corporate development, and M&A. Lipocine is a biopharmaceutical company focused on oral …

Lipocine Inc expected to post a loss of 43 cents a share - Earnings Preview

Lipocine Inc (LPCN) is projected to report a loss of 43 cents per share, according to an earnings preview. The article indicates that more detailed information is available through Reuters on TradingView, which typically requires a subscription to access the full content. This financial …

Lipocine Inc (LPCN) Financial Health: Profitability & Balance Sheet Analysis

The article analyzes the financial health of Lipocine Inc (LPCN), ranking it 268 out of 384 in the Biotechnology & Medical Research industry with a stable financial status but low operating efficiency. The company reported a 27.20% year-over-year revenue increase and a 96.90% net …

Lipocine Inc (LPCN) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Lipocine Inc (LPCN), detailing its current price momentum, support and resistance levels, and signals from various technical indicators and moving averages. The stock currently has a price momentum score of 3.90, ranking it 314 out of 385 …

Lipocine Inc (LPCN) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Lipocine Inc (LPCN), outlining its current TradingKey Stock Score, volatility metrics, and financial risk indicators. LPCN has a risk assessment score of 2.66, ranking 200 out of 385 in the Biotechnology & Medical Research industry, with a …

Lipocine Inc (LPCN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Lipocine Inc (LPCN) as of July 27, 2026. The company's valuation score is 6.81, placing it 287th out of 386 in the Biotechnology & Medical Research industry. Key financial metrics like P/E, P/B, P/S, and P/CF ratios …

Lipocine Inc (LPCN) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Lipocine Inc (LPCN). It indicates that relevant data regarding the company's business segments, regional revenue, and profit contribution have not yet been disclosed by the company. The page also presents basic stock information like its …

Lipocine Inc (LPCN) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure and institutional holdings of Lipocine Inc (LPCN). It lists major shareholders like Squadron Capital Management LLC and Diadema Partners LP, along with their respective proportions. The report also provides a historical overview of institutional shareholding data from Q4 …

Lipocine Inc (LPCN) Cash Flow

This article presents the quarterly and annual cash flow statements for Lipocine Inc (LPCN), focusing on operating, investing, and financing activities. It provides detailed financial figures and year-over-year percentage changes for various cash flow components, allowing users to assess the company's financial health. The …

Lipocine Inc (LPCN) Income Statement

This article provides a detailed quarterly and annual income statement for Lipocine Inc (LPCN), covering various financial metrics from total revenue and operating expenses to net income and earnings per share. It also includes an FAQ section explaining how to read the income statement, …

Lipocine Inc. (LPCN) Q1 2026 Earnings: EPS Miss Pressures Shares as Pipeline Progress Remains Key - Net Profit Margin

Lipocine Market Sentiment

This article analyzes market sentiment for Lipocine (LPCN) through key signals: analyst consensus, short interest, options flow, and insider activity. Analysts have an "Overweight" consensus with a high price target of $33, while short interest is declining, indicating a bullish sentiment. Recent analyst actions, …

LPCN|Lipocine Inc|Price:2.140|Chg%:+0.060

Lipocine Inc. (LPCN) stock is currently trading at $2.140 in after-hours, with an overview of its market performance, financials, and analyst ratings. The company, a biopharmaceutical firm, is focused on developing oral therapeutics for various conditions like postpartum depression, epilepsy, and essential tremor. Despite …

LPCN Q1 2026 Earnings: Wider-Than-Expected Loss Drags Shares Lower - Healthcare Earnings Report

LPCN Forecast — Price Target — Prediction for 2027

Lipocine (LPCN) Reports Q1 Loss, Beats Revenue Estimates

What date does Lipocine's (LPCN) report Earnings - Earnings Calendar & Announcement

Lipocine Inc. (LPCN) stock price, news, quote and history